Product Description
Mechanisms of Action: Sebum Production Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acne Vulgaris
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
DRM01B-ACN05 | P3 |
Completed |
Acne Vulgaris |
2018-04-27 |
|
DRM01B-ACN04 | P3 |
Completed |
Acne Vulgaris |
2017-12-21 |
|
DRM01B-ACN03 | P3 |
Completed |
Acne Vulgaris |
2017-11-28 |